Recommended Immunization Schedule for the Kingdom of Bahrain

		CHILDREN	
AGE		VACCINE	DOSE
At birth	Bacillus Calmette Guerin (BCG) for newb Child Hepatitis B for newborns.	orns born to parents originally from endemic countries.	Single Dose Birth Dose
2 months	Diphtheria and Tetanus toxoid with Pertu vaccine (DTaP-Hib-Hep B-IPV) (as Hexava	ssis, Haemophilus Influenzae type b, hepatitis B, Inactivated Polio alent).	1st Dose
	Pneumococcal Conjugate (PCV).		1st Dose
	Rotavirus vaccine (oral).	ssis, Haemophilus Influenzae type b, hepatitis B and Inactivated	1st Dose
4 months	Polio vaccine (DTaP-Hib-Hep B-IPV) (as F		2nd Dose
	Oral Polio Vaccine (OPV).		2nd Dose
	Pneumococcal Conjugate (PCV).		2nd Dose
	Rotavirus vaccine (oral).	esis Haamonhilus Influenzae tyne h and hanatitis B vaccine	2nd Dose
6 months	Diphtheria and Tetanus toxoid with Pertussis, Haemophilus Influenzae type b and hepatitis B vaccine (DTP-Hib-Hep B) (as Pentavalent). Oral Polio Vaccine (OPV).		3rd Dose
40 !!	Measles, Mumps, Rubella (MMR).		1st Dose
12 months	Varicella (Chickenpox).		1st Dose
15 months	Pneumococcal Conjugate (PCV).		Booster
13 months	Child Hepatitis A.		1st Dose
18 months	Measles, Mumps, Rubella (MMR).		2nd Dose
	Tetravalent (DPT, Hib) or Pentavalent (DT	P-Hib-Hep B) according to availability.	1st Booster
	Oral Polio Vaccine (OPV). Meningococcal ACWY-135 Conjugate.		1st Booster Single Dose
2 years	Child Hepatitis A.		2nd Dose
3 years	Varicella (Chickenpox).		2nd Dose
		ssis vaccine and Inactivated Polio (DTaP-IPV) (as Tetravalent).	2nd Booster
4-5 years	Oral Polio Vaccine (OPV).		2nd Booster
1 Span	Measles, Mumps, Rubella (MMR) if no do	cument of 2 valid doses of MMR vaccination previously.	Catch up dose (if not complete
13 years	Tetanus, diphtheria toxoid, acellular pert	ADOLESCENTS ussis vaccine (Tdap).	Booster
		ISED WOMEN AT REPRODUCTIVE AGE GROUP	
	At first contact Td1.		Td1
Tetanus and diphtheria Toxoid (Td)	At least 4 weeks after Td1.		Td2
	At least 6 months after Td2.		Td3
	One year after Td3. One year after Td 1st booster.		Td 1st booster Td 2nd booster
Tdap	One dose of Tdap in the second or third	trimester can replace one dose of Td	l l l l l l l l l l l l l l l l l l l
Таар		Timoctor can replace one acce of ra.	
	ADOLI, LLDL	ERLY AND HIGH-RISK GROUPS	
Pneumococcal Conjugate vaccine (PCV)	Single dose for adult ≥ 50 years and high		
Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine	 Single dose for adult ≥ 50 years and high Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64 Single revaccination dose after 5 years acquired asplenia, congenital or acquired 	-risk groups.	nalignancy, leukemia, lymphoma,
	 Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64 Single revaccination dose after 5 years acquired asplenia, congenital or acquiratrogenic immunosuppression, solid need a second dose 5 years later. 	years. s recommended to at risk groups including (Sickle cell disease/other bred immuno-deficiencies, chronic renal failure, nephrotic syndrome, n	nalignancy, leukemia, lymphoma,
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular	 Single dose for adult ≥ 50 years and high Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64 Single revaccination dose after 5 years acquired asplenia, congenital or acqui iatrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain the commended in every se	l years. Is recommended to at risk groups including (Sickle cell disease/other be red immuno-deficiencies, chronic renal failure, nephrotic syndrome, norgan transplant). In addition, certain high-risk people vaccinated when of infection and to elderly above 65 years. In categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition).	nalignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap)	 Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64 Single revaccination dose after 5 years acquired asplenia, congenital or acqui iatrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain the certain the commended in every season to certain the commended in every season to certain the certain the commended in every season to certain the certain the commended in every season to certain the c	l years. Is recommended to at risk groups including (Sickle cell disease/other be red immuno-deficiencies, chronic renal failure, nephrotic syndrome, norgan transplant). In addition, certain high-risk people vaccinated when of infection and to elderly above 65 years. In categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition).	nalignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopmer
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine	 Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64 Single revaccination dose after 5 years acquired asplenia, congenital or acqui iatrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain the children ≥6 months and ≤ 5 years, and the commended in every season to certain the conditions incomplete the conditions incomplete the conditions, large the conditions incomplete the conditions, large the conditions incomplete the conditions incomplete the conditions, large the conditions incomplete the conditions at risk to be determined to the commended to at risk groups. Two dosestingle dose to certain high-risk groups. Single dose to certain high-risk groups. Booster dose every 5 years given to certain to the conditions in the complete the conditions. 	lyears. Is recommended to at risk groups including (Sickle cell disease/other be red immuno-deficiencies, chronic renal failure, nephrotic syndrome, morgan transplant). In addition, certain high-risk people vaccinated where of infection and to elderly above 65 years. In categories at risk of infection including: Coluding chronic pulmonary diseases, chronic cardiovascular diseases, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition).	nalignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopment oart for ≥ 13 years of age.
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine	 Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64 Single revaccination dose after 5 years acquired asplenia, congenital or acquiratrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain the children ≥6 months and ≤ 5 years, and the children ≥6 months and ≤ 5 years, and the children ≥6 months and ≤ 5 years, and the conditions incomplete the conditions, Immune-suppressed individuals at higher risk of the conditions are conditions, Immune-suppressed individuals at higher risk of the conditions are conditions. Certain chronic medical conditions in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the conditions are conditions. Certain chronic medical conditions in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the conditions are conditions. Pregnant women, Health care workers Other categories at risk to be determined at risk groups. Single dose to certain high-risk groups. Booster dose every 5 years given to conditions are conditions. Single dose for >5 years of age having an are conditions. 	lyears. Is recommended to at risk groups including (Sickle cell disease/other by the series immuno-deficiencies, chronic renal failure, nephrotic syndrome, morgan transplant). In addition, certain high-risk people vaccinated where of infection and to elderly above 65 years. I categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, ders, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). Interest in the series of age and as 2 doses 4 weeks age and travelers to Holly places, meningitis belt countries and countries extain categories remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection.	nalignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopment out for ≥ 13 years of age. Se reporting outbreak. ia or functional (including sickle
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine	 Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64 Single revaccination dose after 5 years acquired asplenia, congenital or acquiratrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain the children ≥6 months and ≤ 5 years, and the children ≥6 months and ≤ 5 years, and the children ≥6 months and ≤ 5 years, and the conditions incomplete the conditions, Immune-suppressed individuals at higher risk of the conditions are conditions, Immune-suppressed individuals at higher risk of the conditions are conditions. Certain chronic medical conditions in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the conditions are conditions. Certain chronic medical conditions in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the conditions are conditions. Pregnant women, Health care workers Other categories at risk to be determined at risk groups. Single dose to certain high-risk groups. Booster dose every 5 years given to conditions are conditions. Single dose for >5 years of age having an are conditions. 	lyears. Is recommended to at risk groups including (Sickle cell disease/other by the first immuno-deficiencies, chronic renal failure, nephrotic syndrome, norgan transplant). In addition, certain high-risk people vaccinated where the first infection and to elderly above 65 years. In categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, ders, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). In the distribution of the first including diabetes and countries are and travelers to Holly places, meningitis belt countries and countries entain categories remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection. By of the following conditions:	nalignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopment out for ≥ 13 years of age. Se reporting outbreak. ia or functional (including sickle
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine Haemophilus Influenza type b vaccine (Hib)	 Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64 Single revaccination dose after 5 years acquired asplenia, congenital or acquiratrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain the conditions and ≤ 5 years, and the conditions incompatible of the conditions, lambure-suppressed individuals at higher risk of the conditions in the conditions in the patic diseases, chronic blood disord conditions, lambure-suppressed individuals at higher risk of the conditions, lambure-suppressed individuals at higher risk of the conditions are conditions and the conditions in the patic diseases, chronic blood disord conditions, lambure-suppressed individuals at higher risk of the conditions are conditions. Certain chronic medical conditions in the patic diseases, chronic blood disord conditions, lambure-suppressed individuals at higher risk of the conditions are conditions. Certain chronic medical conditions in the patic diseases, chronic blood disord conditions. Pregnant women, Health care workers Other categories at risk to be determined at risk groups. Single dose to certain high-risk groups. Booster dose every 5 years given to conditions in the patic disease, chronic blood disord conditions. Single dose to certain high-risk groups. Anatomical or functional asplenia (inc.) 	lyears. Is recommended to at risk groups including (Sickle cell disease/other by the street immuno-deficiencies, chronic renal failure, nephrotic syndrome, norgan transplant). In addition, certain high-risk people vaccinated where the street infection and to elderly above 65 years. In categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). In the street in the street including diabetes and as 2 doses 4 weeks appeared by treating physician. In the see, 3 months apart from 1 -12 years of age and as 2 doses 4 weeks appeared to the street incategories remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection. In the street in the street incategories remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection. In the street incategories remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection. In the street incategories remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection. In the street incategories remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection. In the street incategories remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection.	nalignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopment of the control of the con
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine	 Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64 Single revaccination dose after 5 years acquired asplenia, congenital or acquiratrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain the conditions and ≤ 5 years, and the conditions incomplete the conditions, lambda the conditions incomplete the conditions, lambda the conditions, lambda the conditions, lambda the conditions, lambda the conditions in the patic diseases, chronic blood disord conditions, lambda the conditions, lambda the conditions in the patic diseases, chronic blood disord conditions, lambda the conditions, lambda the conditions in the patic diseases, chronic blood disord conditions, lambda the conditions in the patic diseases, chronic blood disord conditions, lambda the conditions in the patic diseases at risk to be determined. The conditions in the patic disease at risk to be determined to the conditions and the conditions in the patic disease at risk to be determined. The conditions is the conditions in the patic disease at risk to be determined to the conditions in the patic disease at risk to be determined to the conditions at risk groups. Two dosestic diseases, persistent complement to the conditions are conditional asplenia (incomplete disease), persistent complement to the conditions are conditions. Single dose for >5 years of age having an another conditions and the conditions are conditions. Single dose. 	lyears. Is recommended to at risk groups including (Sickle cell disease/other by the street immuno-deficiencies, chronic renal failure, nephrotic syndrome, norgan transplant). In addition, certain high-risk people vaccinated where the street infection and to elderly above 65 years. In categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). In the street in the street including diabetes and as 2 doses 4 weeks appeared by treating physician. In the see, 3 months apart from 1 -12 years of age and as 2 doses 4 weeks appeared to the street incategories remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection. In the street in the street incategories remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection. In the street incategories remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection. In the street incategories remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection. In the street incategories remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection. In the street incategories remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection.	nalignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopment of the control of the con
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine Haemophilus Influenza type b vaccine (Hib)	 Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64 Single revaccination dose after 5 years acquired asplenia, congenital or acquiratrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain the conditions and ≤ 5 years, and the conditions incomplete the conditions, lambda the conditions incomplete the conditions, lambda the conditions, lambda the conditions, lambda the conditions, lambda the conditions in the patic diseases, chronic blood disord conditions, lambda the conditions, lambda the conditions in the patic diseases, chronic blood disord conditions, lambda the conditions, lambda the conditions in the patic diseases, chronic blood disord conditions, lambda the conditions in the patic diseases, chronic blood disord conditions, lambda the conditions in the patic diseases at risk to be determined. The conditions in the patic disease at risk to be determined to the conditions and the conditions in the patic disease at risk to be determined. The conditions is the conditions in the patic disease at risk to be determined to the conditions in the patic disease at risk to be determined to the conditions at risk groups. Two dosestic diseases, persistent complement to the conditions are conditional asplenia (incomplete disease), persistent complement to the conditions are conditions. Single dose for >5 years of age having an another conditions and the conditions are conditions. Single dose. 	years. s recommended to at risk groups including (Sickle cell disease/other by the common organ transplant). In addition, certain high-risk people vaccinated where of infection and to elderly above 65 years. It categories at risk of infection including: Coluding chronic pulmonary diseases, chronic cardiovascular diseases, chers, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). The description of the column of	nalignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopme part for ≥ 13 years of age. Se reporting outbreak. It is or functional (including sickle
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine (Hib) Meningococcal ACWY-135 Conjugate vaccine	 Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acqui iatrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain event in the conditions of the conditions in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals in the patic diseases in the patic blood disord conditions. Pregnant women, Health care workers Other categories at risk to be determined by the patic disease, persistent complement of the patic disease. Single dose for >5 years of age having an example and the patic disease of the patic disease. Single dose. Single dose. Booster doses every 5 years recommended for every season. 	lyears. Is recommended to at risk groups including (Sickle cell disease/other by serious immuno-deficiencies, chronic renal failure, nephrotic syndrome, morgan transplant). In addition, certain high-risk people vaccinated where of infection and to elderly above 65 years. It categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, clers, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). Interest of the following physician. Interest of the following remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection. Interest of the following conditions: Inding sickle cell disease), post bone marrow transplant and certain cated the following sickle cell disease). Interest of the following conditions: Inding sickle cell disease) of the following conditions: Inding sickle cell disease of the	nalignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopme part for ≥ 13 years of age. Se reporting outbreak. It is or functional (including sickle
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine (Hib) Meningococcal ACWY-135 Conjugate vaccine	Single dose for adult ≥ 50 years and high Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acqui iatrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain the children ≥6 months and ≤ 5 years, and the patic diseases, chronic blood disord conditions, Immune-suppressed individuals the patic diseases, chronic blood disord conditions, Immune-suppressed individuals are workers. The patic diseases at risk to be determined by the patic disease at risk to be determined by the patic disease at risk to be determined by the patic disease at risk groups. Two dosestingle dose to certain high-risk groups. Booster dose every 5 years given to concell disease), persistent complement of the patic dose for >5 years of age having an another dosester doses every 5 years recommended. Single dose. Single dose. Single dose. Booster doses every 5 years recommended for every season.	lyears. Is recommended to at risk groups including (Sickle cell disease/other by the following conditions: In addition, certain high-risk people vaccinated when the infection and to elderly above 65 years. In categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, ders, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). In additions or by disease condition including diabetes mellitus, chronic iduals by medications or by disease condition. In additions or by disease condition including diabetes mellitus, chronic iduals by medications or by disease condition. In additions or by disease condition including diabetes mellitus, chronic iduals by medications or by disease condition. In additions or by disease condition including diabetes mellitus, chronic iduals by medications or by disease condition. In additions or by disease condition including diabetes mellitus, chronic iduals by medications or by disease condition. In addition, certain given including diabetes mellitus, chronic iduals by medications or by disease condition. In addition, certain given including diabetes mellitus, chronic iduals by medications or by disease condition. In addition, certain given including diabetes mellitus, chronic iduals by medications or by disease, chronic cardiovascular diseases, chronic	n younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopme part for ≥ 13 years of age. reporting outbreak. ia or functional (including sickle ancer after completion of treatme
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine Haemophilus Influenza type b vaccine (Hib) Meningococcal ACWY-135 Conjugate vaccine Seasonal Influenza vaccine	 Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acqui iatrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain event in the conditions of the conditions in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals in the patic diseases, chronic blood disord conditions, Immune-suppressed individuals in the patic diseases in the patic blood disord conditions. Pregnant women, Health care workers Other categories at risk to be determined by the patic disease, persistent complement of the patic disease. Single dose for >5 years of age having an example and the patic disease of the patic disease. Single dose. Single dose. Booster doses every 5 years recommended for every season. 	lyears. Is recommended to at risk groups including (Sickle cell disease/other by serious immuno-deficiencies, chronic renal failure, nephrotic syndrome, morgan transplant). In addition, certain high-risk people vaccinated where of infection and to elderly above 65 years. It categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, clers, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). Interest of the following physician. Interest of the following remain at risk of infection such as anatomical asplent component deficiency and people with HIV infection. Interest of the following conditions: Inding sickle cell disease), post bone marrow transplant and certain cated the following sickle cell disease). Interest of the following conditions: Inding sickle cell disease) of the following conditions: Inding sickle cell disease of the	n younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopme part for ≥ 13 years of age. reporting outbreak. ia or functional (including sickle ancer after completion of treatme
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine (Hib) Meningococcal ACWY-135 Conjugate vaccine	Single dose for adult ≥ 50 years and high Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acqui iatrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain the children ≥6 months and ≤ 5 years, and the patic diseases, chronic blood disord conditions, Immune-suppressed individuals the patic diseases, chronic blood disord conditions, Immune-suppressed individuals are workers. The patic diseases at risk to be determined by the patic disease at risk to be determined by the patic disease at risk to be determined by the patic disease at risk groups. Two dosestingle dose to certain high-risk groups. Booster dose every 5 years given to concell disease), persistent complement of the patic dose for >5 years of age having an another dosester doses every 5 years recommended. Single dose. Single dose. Single dose. Booster doses every 5 years recommended for every season.	lyears. Is recommended to at risk groups including (Sickle cell disease/other by the following conditions: In addition, certain high-risk people vaccinated when the infection and to elderly above 65 years. In categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, ders, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). In additions or by disease condition including diabetes mellitus, chronic iduals by medications or by disease condition. In additions or by disease condition including diabetes mellitus, chronic iduals by medications or by disease condition. In additions or by disease condition including diabetes mellitus, chronic iduals by medications or by disease condition. In additions or by disease condition including diabetes mellitus, chronic iduals by medications or by disease condition. In additions or by disease condition including diabetes mellitus, chronic iduals by medications or by disease condition. In addition, certain given including diabetes mellitus, chronic iduals by medications or by disease condition. In addition, certain given including diabetes mellitus, chronic iduals by medications or by disease condition. In addition, certain given including diabetes mellitus, chronic iduals by medications or by disease, chronic cardiovascular diseases, chronic	nalignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopme oart for ≥ 13 years of age. Se reporting outbreak. It is or functional (including sickle ancer after completion of treatme
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine Haemophilus Influenza type b vaccine (Hib) Meningococcal ACWY-135 Conjugate vaccine Seasonal Influenza vaccine	 Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acqui iatrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain every certain chronic medical conditions incomplete health of the conditions incomplete health care workers. Certain chronic medical conditions incomplete health care workers. Other categories at risk to be determined becommended to at risk groups. Two dosest conditions are cell disease), persistent complement of the cell disease), persistent complement of the cell disease. Single dose for >5 years of age having an example having	lyears. Is recommended to at risk groups including (Sickle cell disease/other by red immuno-deficiencies, chronic renal failure, nephrotic syndrome, norgan transplant). In addition, certain high-risk people vaccinated where of infection and to elderly above 65 years. It categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). In the description of the provided in the p	nalignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopme oart for ≥ 13 years of age. Se reporting outbreak. It is or functional (including sickle ancer after completion of treatme
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine Haemophilus Influenza type b vaccine (Hib) Meningococcal ACWY-135 Conjugate vaccine Seasonal Influenza vaccine Travelers (according to	Single dose for adult ≥ 50 years and high Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acqui iatrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain to the children ≥6 months and ≤ 5 years, and the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the patic diseases, chronic blood disord conditions, Immune-suppressed individuals are workers. Other categories at risk to be determined to the categories at risk to be determined to at risk groups. Two dosest commended to at risk groups. Two dosest lates are sold in the patic disease), persistent complement of the categories at risk to be determined to the categories at risk to be determined by the categories at r	years. s recommended to at risk groups including (Sickle cell disease/other be red immuno-deficiencies, chronic renal failure, nephrotic syndrome, norgan transplant). In addition, certain high-risk people vaccinated where of infection and to elderly above 65 years. It categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, deers, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). Indeed by treating physician. Indeed by treating physician. Indeed by treating physician. Indeed by treating physician at risk of infection such as anatomical asplementation categories remain at risk of infection such as anatomical asplementation categories remain at risk of infection such as anatomical asplementation component deficiency and people with HIV infection. Indeed by treating physician and certain categories at risk of infection. Indeed by treating physician. Indeed b	analignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopme part for ≥ 13 years of age. So reporting outbreak. Sia or functional (including sickle ancer after completion of treatments) ated).
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine Haemophilus Influenza type b vaccine (Hib) Meningococcal ACWY-135 Conjugate vaccine Seasonal Influenza vaccine Travelers (according to travel destination)	Single dose for adult ≥ 50 years and high Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acqui iatrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain to the children ≥ 6 months and ≤ 5 years, the conditions incompation of the patic diseases, chronic blood disord conditions, Immune-suppressed indivious the pregnant women, the Health care workers to the categories at risk to be determined. The commended to at risk groups. Two dosesting the commended to a trisk groups. Two dosesting the conditions are conditions, persistent complement to the compation of the commended to a trisk groups. Two dosesting the commended to a trisk groups. Two dosesting the conditions are conditions and the commended to a trisk groups. Two dosesting the conditions are conditions and the commended to a trisk groups. Two dosesting the conditions are conditions and the conditions are conditions. The conditions are conditions are conditions are conditions and the conditions are conditions. The conditions are conditions are conditions are conditions are conditions. The conditions are conditions are conditions are conditions are conditions. The conditions are conditions are conditions are conditions are conditions. The conditions are conditions are conditions are conditions are conditions. The conditions are conditions are conditions are conditions. The conditions are conditions are conditions are conditions are conditions. The conditions are conditions are conditions are conditions. The conditions are conditions are conditions are conditions. The conditions are conditions are conditions are conditions are conditions. The conditions are conditions are conditions are conditions. The conditions are conditions are conditions. The conditions are conditions are conditions are conditions. The conditions are conditions are conditions. The con	Lyears. Is recommended to at risk groups including (Sickle cell disease/other by recommended to at risk groups including (Sickle cell disease/other by red immuno-deficiencies, chronic renal failure, nephrotic syndrome, norgan transplant). In addition, certain high-risk people vaccinated where the properties of infection and to elderly above 65 years. It categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). In the depth of the properties of the pr	analignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopme part for ≥ 13 years of age. So reporting outbreak, in or functional (including sickle ancer after completion of treatme atted).
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine Haemophilus Influenza type b vaccine (Hib) Meningococcal ACWY-135 Conjugate vaccine Seasonal Influenza vaccine Travelers (according to travel destination) Post exposure prophylaxis (depend on exposure and risk category)	Single dose for adult ≥ 50 years and high Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acqui iatrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain to the children ≥6 months and ≤ 5 years, and the conditions incomplete the conditions, leading to the conditions incomplete the conditions, leading to the conditions in the conditions, leading to the conditions, leading to the conditions, leading to the conditions, leading to the conditions in the least to the conditions, leading to the conditions, leading to the conditions, leading to the conditions at risk to be determined. Recommended to at risk groups. Two dosester dose every 5 years given to conditions and the conditions are conditional asplenia (incomplete dose), persistent complement to conditions and the conditions are complete to conditions. Single dose for >5 years of age having and the conditions are complete to conditions. Single dose for >5 years of age having and the conditions are complete to conditions. Single dose for years of age having and the conditions are complete to conditions. Personant women, the conditions in the conditions are conditions and the conditions are conditions. Single dose for years of age having and the conditions are conditions. Single dose for years of age having and the conditions are conditions. Recommended for every season.	lyears. Is recommended to at risk groups including (Sickle cell disease/other bred immuno-deficiencies, chronic renal failure, nephrotic syndrome, norgan transplant). In addition, certain high-risk people vaccinated where of infection and to elderly above 65 years. It categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, ders, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). In the description of the provided in the	analignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopment of the completion of treatment of the completion of treatment of treatment of the completion of the complet
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine Haemophilus Influenza type b vaccine (Hib) Meningococcal ACWY-135 Conjugate vaccine Seasonal Influenza vaccine Travelers (according to travel destination) Post exposure prophylaxis (depend on exposure and risk category) Individuals at risk of hepatitis (household and sexual contacts of chronic	Single dose for adult ≥ 50 years and high Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acqui iatrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain conditions and ≤ 5 years, and the patic diseases, chronic blood disord conditions, Immune-suppressed indivies are pregnant women, and the patic diseases, chronic blood disord conditions, Immune-suppressed indivies are pregnant women, and the patic diseases are risk to be determined. Becommended to at risk groups. Two dosestic dose every 5 years given to concell disease), persistent complement of the complete conditions are pregnant women, and the patic disease of the pregnant women, and the pregnant women, and the pregnant women, and the pregnant women, are pregnant women, and the pregnant women,	lyears. Is recommended to at risk groups including (Sickle cell disease/other be red immuno-deficiencies, chronic renal failure, nephrotic syndrome, norgan transplant). In addition, certain high-risk people vaccinated where of infection and to elderly above 65 years. It categories at risk of infection including: Colluding chronic pulmonary diseases, chronic cardiovascular diseases, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). In the dispersion of the provided in the pr	nalignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopmer part for ≥ 13 years of age. So reporting outbreak, in or functional (including sickle ancer after completion of treatmer atted).
Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine Haemophilus Influenza type b vaccine (Hib) Meningococcal ACWY-135 Conjugate vaccine Seasonal Influenza vaccine Travelers (according to travel destination) Post exposure prophylaxis (depend on exposure and risk category) Individuals at risk of hepatitis	Single dose for adult ≥ 50 years and high Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acqui iatrogenic immunosuppression, solid need a second dose 5 years later. Single dose to individuals at higher risk of the commended in every season to certain conditions and ≤ 5 years, and the patic diseases, chronic blood disord conditions, Immune-suppressed indivies are pregnant women, and the patic diseases, chronic blood disord conditions, Immune-suppressed indivies are pregnant women, and the patic diseases are risk to be determined. Becommended to at risk groups. Two dosestic dose every 5 years given to concell disease), persistent complement of the complete conditions are pregnant women, and the patic disease of the pregnant women, and the pregnant women, and the pregnant women, and the pregnant women, are pregnant women, and the pregnant women,	lyears. Is recommended to at risk groups including (Sickle cell disease/other bred immuno-deficiencies, chronic renal failure, nephrotic syndrome, norgan transplant). In addition, certain high-risk people vaccinated where of infection and to elderly above 65 years. It categories at risk of infection including: Cluding chronic pulmonary diseases, chronic cardiovascular diseases, ders, chronic metabolic disorders including diabetes mellitus, chronic iduals by medications or by disease condition). In the description of the provided in the	nalignancy, leukemia, lymphoma, in younger than age 65 years will chronic renal diseases, chronic neurologic and neurodevelopmen oart for ≥ 13 years of age. Se reporting outbreak. ia or functional (including sickle ancer after completion of treatmen atted).